Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

A synthetic GnRH agonist decapeptide that suppresses gonadotropin and sex hormone production for treating prostate cancer, endometriosis, and precocious puberty.

Quick Stats
Studies 178
Trials 100
Formula C64H82N18O13
Clear All
Utility 2
pubmed Sep 8, 2024

The Protective Effect of GnRH Agonist Triptorelin on the Histomorphometric Parameters of the Utero-ovarian Tissue in the Doxorubicin- and Cyclophosphamide-treated Mice.

Bahmanpour. Soghra S; Ameri. Negin N; Zareifard. Nehleh N; Karimi. Fatemeh F

In mice, giving the hormone drug triptorelin before or after chemotherapy helped keep the ovaries and uterus healthier. It boosted the number of early‑stage egg follicles, cut down dying follicles, and kept the size of ovarian and uterine tissues normal, showing it can protect reproductive organs from chemo damage.

Utility 2
pubmed Jul 16, 2024

CDK4/6 and aromatase inhibitors as first-line treatment in metastatic high-grade neuroendocrine carcinoma of the breast: A case report.

Zouki. Dionysia N DN; Kardara. Vasiliki-Elpida VE; Ioannou. Stephanie S; Arvanitou. Eleni E; Exarcho...

A rare type of breast cancer that makes hormones can shrink dramatically when treated with a mix of hormone blockers (letrozole and triptorelin) plus a cell‑cycle drug (palbociclib). This case shows that targeting estrogen signals together with stopping cells from dividing may work well as a first treatment, but it’s based on one patient and needs doctor oversight.

Utility 2
pubmed Jul 3, 2024

PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer.

Matveev. Vsevolod V; Gao. Xin X; Kopyltsov. Evgeny E; Luo. Jindan J; Wei. Qiang Q; Ye. Dingwei D; Zh...

In men who had their prostate removed for high‑risk cancer, getting the hormone‑blocking drug triptorelin for about nine months seemed to keep the cancer marker (PSA) low a bit longer than doing nothing, but the difference wasn’t strong enough to be sure it really works. The drug kept testosterone very low in most patients and didn’t cause major safety problems.

Utility 2
pubmed May 1, 2025

In vitro assessment of polyethylene glycol-coated iron oxide nanoparticles integrating luteinizing hormone releasing-hormone targeted magnetic hyperthermia and doxorubicin for lung and breast cancer cells.

Srivastava. Neha N; Chudasama. Bhupendra B; Baranwal. Manoj M

Scientists attached the peptide triptorelin to tiny iron‑oxide particles coated with PEG, loaded them with the chemo drug doxorubicin, and used a magnetic field to heat them. In lab tests on lung and breast cancer cells, the combined heat‑plus‑drug treatment killed most of the cells, more than either heat or drug alone, and also raised an immune signal. The work shows a promising way to deliver cancer drugs more precisely, but it’s still early‑stage lab research, not a ready‑to‑use protocol for everyday health optimization.

Utility 2
pubmed Feb 25, 2025

A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia.

Yee. Chi-Hang CH; Chung. Yuen-Hei YH; Ko. Ivan Ching-Ho IC; Wong. Chris Ho-Ming CH; Mok. Alex A; Teo...

A study in Asia looked at how well a long‑acting form of the hormone‑blocking drug triptorelin works in men with advanced prostate cancer. Over half the patients stayed on the drug for a long time, most had their testosterone dropped to very low levels, and side effects were rare.

Utility 2
pubmed Oct 16, 2024

A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.

Yu. Xiao X; Cheng. Xinran X; Wei. Haiyan H; Xu. Xu X; Gong. Chunxiu C; Li. Guimei G; Yao. Hui H; Zho...

A 6‑month triptorelin injection (22.5 mg) given twice a year completely shut down the hormone signals that drive puberty in Chinese children, and the effect lasted up to a year with only mild side‑effects. Growth slowed and bone age caught up to calendar age, showing the drug can pause development safely. The study shows the long‑acting formulation works well, but it was done in kids, not adults.

Utility 2
pubmed May 8, 2025

Effects of Different Gonadotropin-Releasing Hormone Agonists on IVF/ICSI-ET Outcomes in Long Protocol: A Retrospective Study.

Xu. Min M; Li. Honglin H; Zhao. Yiyan Y; Li. Huimei H; Zhao. Chao C; Zhang. Xi X; Ni. Rong R; Liang....

A study compared three GnRH‑agonist drugs (triptorelin, leuprorelin, goserelin) used in IVF cycles and found that goserelin required less total hormone and fewer days of dosing, and showed slightly higher pregnancy and live‑birth rates, though the differences weren’t statistically proven.

Utility 2
pubmed Sep 12, 2024

Case report: Epilepsy during the use of recombinant human growth hormone: a report on two cases and a literature review.

Zhou. Yuan Y; Jia. Ruofan R; Xu. Zhuangjian Z; Ma. Yaping Y

In two Chinese boys, seizures started while they were on growth‑hormone injections. Stopping the hormone stopped the seizures, while stopping the other drug (triptorelin) didn’t help. This suggests growth hormone, not triptorelin, may trigger epilepsy in kids with certain risk factors.

Utility 2
pubmed Nov 7, 2024

Stepwise approach of hysteroscopic cytoreductive surgery for adenomyosis in patients with recurrent implantation failure.

Campo. Rudi R; Gillet. Evy E; Gordts. Stephan S; Valkenburg. Marion M; Van Kerrebroeck. Helena H; Su...

A small study showed that a minimally invasive hysteroscopic surgery, combined with monthly shots of the peptide drug triptorelin, helped women under 37 with adenomyosis and failed IVF attempts get pregnant, with few complications and healthy babies.

Utility 2
pubmed Jul 9, 2025

Apalutamide-associated rash combined with severe neutropenia and eosinophilia: a case report.

Shao. Yuan Y; Liu. Zihao Z; Zhang. Yinchi Y; Yang. Zhen Z; Liu. Yang Y; Huang. Hua H; Wang. Zeyuan Z...

A 74‑year‑old man on the prostate cancer drug apalutamide developed a severe skin rash, fever, very low neutrophil counts, and high eosinophils about six weeks after starting the medication. Stopping apalutamide and treating him with antihistamines, antibiotics, steroids, and a growth factor for neutrophils cleared the rash and normalized his blood counts. He is now being kept on the hormone‑blocking peptide triptorelin instead, with his PSA under control.

Utility 2
pubmed Feb 1, 2025

An Unusual Presentation of Costello Syndrome in a Boy with Precocious Puberty and Chiari I Malformation: A Case Report.

Lages Pereira. Rita R; Ribeiro. Ana A; Saraiva. João J; Soares-Fernandes. J P JP; Gonçalve...

A boy with a rare genetic condition called Costello syndrome started puberty unusually early. Doctors gave him a drug called triptorelin, which is a hormone blocker, and it helped slow down his puberty and keep his growth more on track. This case shows that triptorelin can be useful for managing early puberty even in complex genetic cases, but it’s a very specific situation.

Utility 2
pubmed Aug 30, 2024

Central Precocious Puberty in a Male Child With Down Syndrome: A Case Report.

Al Noaim. Khalid K

A 7‑year‑old boy with Down syndrome developed early puberty and was treated with the peptide drug triptorelin, first as a monthly injection (3.75 mg) and later as a three‑monthly injection (11.25 mg). After three years his testicles got smaller, hormone levels dropped, and he had no reported side effects, suggesting the treatment worked well for his condition.

Utility 2
pubmed May 5, 2025

Efficacy of first-year GnRHa therapy in girls with idiopathic central precocious puberty diagnosed after age 8: a retrospective study.

Ni. Ming-Ming MM; Yang. Shu-Ting ST; Sun. Jie-Yu JY; Wu. Wen-Wen WW; Li. Man M; Gu. Wei W; Ji. Xing...

The study shows that using the peptide drug triptorelin (a GnRH agonist) in girls with early puberty can effectively pause puberty, slow bone growth, and help them grow taller, especially if treatment starts before age 8. It didn’t change their body weight.

Utility 2
pubmed Oct 16, 2021

Capillary Electrophoresis-Mass Spectrometry with Multisegment Injection and In-Capillary Preconcentration for High-Throughput and Sensitive Determination of Therapeutic Decapeptide Triptorelin in Pharmaceutical and Biological Matrices.

Piešťanský. Juraj J; Čižmárová. Ivana I; Štefánik....

Researchers created a fast, sensitive lab test that can accurately measure the peptide drug triptorelin in medicines and blood samples, using a special capillary electrophoresis‑mass spectrometry technique.

Utility 2
pubmed Sep 5, 2023

Unveiling the Effects of Triptorelin on Endocrine Profiles: Insights From Healthy, Polycystic Ovary Syndrome, and Hypothalamic Amenorrhea Women.

Kumari. Riya R; Muneshwar. Komal N KN; Pathade. Aniket G AG; Yelne. Seema S

The paper reviews how triptorelin, a synthetic hormone that first spikes and then dampens the reproductive hormone system, is used in healthy women for fertility treatments and shows promise for helping women with PCOS or hypothalamic amenorrhea regain normal hormone cycles, but it’s mainly a clinical overview, not a new DIY protocol.

Utility 2
pubmed Mar 11, 2024

Changes in Quality of Life and Sexual Function After Luteinizing Hormone-Releasing Hormone (LHRH) Agonists and Orchiectomy in Men With Metastatic Prostate Cancer: Results From a Randomized Trial.

Dissing. Niklas N; Fode. Mikkel M; Østergren. Peter P; Sønksen. Jens J

In men with advanced prostate cancer, starting hormone therapy with triptorelin or having the testicles removed led to better overall quality of life and mood, fewer urinary problems, but more hormone‑related side effects and a big drop in sexual activity. The drug and surgery worked about the same.

Utility 2
pubmed Aug 16, 2023

Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.

Luo. Xiaoping X; Zhang. Cai C; Yang. Yu Y; Xu. Xu X; Cheng. Xinran X; Wei. Haiyan H; Wang. Lanying L...

A study in Chinese kids with early puberty showed that a 3‑month injectable form of the peptide triptorelin effectively lowered puberty hormones in almost all participants and was well tolerated, with growth speed slowing and bone age catching up to calendar age.

Utility 2
pubmed Jun 1, 2023

Effects of water-soluble additive on the release profile and pharmacodynamics of triptorelin loaded in PLGA microspheres.

He. Xiaoyan X; Liu. Jiwei J; Song. Tao T; Sun. Yiying Y; Lu. Xiaoyan X; Li. Nuannuan N; Sun. Kaoxian...

Researchers tested three water‑soluble additives (salt, calcium chloride, and glucose) in PLGA microspheres that slowly release the hormone‑blocking peptide triptorelin. All three gave a similar early burst, but only the glucose‑added microspheres kept releasing the drug steadily, leading to longer suppression of testosterone. The slower release is linked to the microsphere’s glass transition temperature dropping, which lets the polymer shrink and close pores after the first burst.

Utility 2
pubmed Jun 30, 2023

Triptorelin nanoparticle-loaded microneedles for use in assisted reproductive technology.

Lu. Xiaoyan X; Sun. Yiying Y; Han. Meishan M; Chen. Daoyuan D; He. Xiaoyan X; Wang. Siqi S; Sun. Kao...

Scientists made a tiny skin patch with silk‑based microneedles that can slowly release the fertility drug triptorelin through the skin, instead of daily injections. In rats the patch let more of the drug get into the bloodstream, kept it around longer, and boosted hormone levels that are needed for assisted reproduction. While promising, the technology is still experimental and not yet available for personal use.